Research article summary (published 5 Jul 2006):

Laboratory parameter profiles among patients with cystic fibrosis.

Full Abstract

BACKGROUND:
Clinical trials in cystic fibrosis (CF) currently use laboratory-specific reference ranges to evaluate chemistry and hematology measurements. Laboratory-specific normal reference ranges may not accurately reflect what is abnormal but clinically insignificant among CF patients.

METHODS:
To address this concern, data from the Phase III trial of inhaled tobramycin in CF patients was used to describe the distribution and variability of laboratory parameters. The laboratory specimens were analyzed at a central laboratory after being obtained at baseline and throughout the 24-week trial.

RESULTS:
At the time of entry into the clinical trial, 91% (463 of 508) of patients had at least a single value outside the normal range. Liver function tests (AST, ALT) were above the normal range in 16% and 12% of the patients respectively, with 2.4% of patients having an AST>2.0 times the upper limit of normal. Of the 243 patients on placebo, 242 (99.6%) had at least one laboratory parameter that changed from normal to abnormal during the 24-week follow-up period. Of those same placebo patients, 11.5% (N=28) had a laboratory parameter change from a Common Toxicity Criteria (CTC) grade 0 to grade 2 or higher during follow-up.

CONCLUSIONS:
Patients with CF frequently have laboratory values outside the normal range and have significant longitudinal variability of laboratory values. Interpretation of adverse events in the clinical trial setting may be complicated by the underlying high rates of some laboratory abnormalities in the CF population. This data was presented in poster format at the American Thoracic Society International Conference, Atlanta, USA, 2002, appearing subsequently in the Conference proceedings [Goss CH, Mayer-Hamblett N, Yunker A, Waltz DA, Kronmal RA, Ramsey BW. Laboratory parameter profiles among patients with cystic fibrosis. Am J Rep Crit Care Med 2002;165(8):A283].

Learn Faster Today      Improve your study skills

Author information

Author/s: Goss, Christopher H (CH); Mayer-Hamblett, Nicole (N); Kronmal, Richard A (RA); Williams, Judy (J); Ramsey, Bonnie W (BW);

Affiliation: Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA. goss(-atsign-)u.washington.edu

Grants: MO1-RR00037 (Agency:NCRR NIH HHS)

Journal and publication information

Publication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (J Cyst Fibros), published in Netherlands. (Language: eng)

Reference: 2007-Apr; vol 6 (issue 2) : pp 117-23

Dates: Created 2007/03/19; Completed 2007/06/19; Revised 2007/11/15;

PMID: 16829217, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adolescent Alanine Transaminase - metabolism Anti-Bacterial Agents - therapeutic use Aspartate Aminotransferases - metabolism Child Clinical Trials, Phase III as Topic Cross-Sectional Studies Cystic Fibrosis - therapy Cystic Fibrosis Transmembrane Conductance Regulator - genetics; metabolism Double-Blind Method

Double-Blind Method Female Humans Laboratory Techniques and Procedures Liver Function Tests Longitudinal Studies Male Placebos Reference Values Tobramycin - therapeutic use

Associated Chemicals: Anti-Bacterial Agents (0) ; CFTR protein, human (0) ; Placebos (0) ; Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) ; Tobramycin (32986-56-4) ; Aspartate Aminotransferases (EC 2.6.1.1) ; Alanine Transaminase (EC 2.6.1.2)

Related articles

These are the highest related articles currently in the database:

• Cystic fibrosis: ironing out the problem of infection? 14 May 2008
• What did we learn from the North American Cystic Fibrosis Conference? 29 Jun 2008
• Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. 30 Jul 2008
• Accuracy and potential usefulness of triplex real-time PCR for improving antibiotic treatment of patients with blood cultures showing clustered gram-positive cocci on direct smears. 14 Apr 2008
• Antibiotics for respiratory, ear and urinary tract disorders and consistency among GPs. 8 Jun 2008
• Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. 29 Apr 2008
• Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne. 30 May 2008
• Safety and efficacy of long-term treatment with linezolid in cystic fibrosis: case report. 30 May 2008
• Colloidal silver for lung disease in cystic fibrosis. 29 Jun 2008
• Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-months randomized clinical trial. 7 Jul 2008

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.